Mink therapeutics announces appointment of dr. robert kadlec to board of directors

New york, oct. 31, 2024 (globe newswire) -- mink therapeutics (mink, nasdaq: inkt), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer t (inkt) cell therapies, today announced the appointment of dr. robert kadlec to its board of directors. dr. kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning mink to accelerate its innovative inkt cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ards), emerging threats, and immune related diseases.
INKT Ratings Summary
INKT Quant Ranking